Skip to content

Advertisement

  • Poster presentation
  • Open Access

Safety of vacuum-assisted biopsy/mammatome guided, non-operative management of B3 lesions with atypia: a 7-year follow-up study

  • 1, 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Breast Cancer Research201517 (Suppl 1) :P31

https://doi.org/10.1186/bcr3793

  • Published:

Keywords

  • Carcinoma
  • Diagnostic Accuracy
  • Benign Lesion
  • Single Centre
  • Invasive Carcinoma

Introduction

B3 management balances safe treatment of potential malignancy against the morbidity of surgical excision of benign lesions. Vacuum-assisted biopsy (VAB) increases diagnostic accuracy, removing some lesions entirely without surgery. Few follow-up data are available to assess the safety and effectiveness of this approach.

Methods

A total of 129 patients with B3 VAB with atypia were identified using Labcentre histopathology codes at a single centre. Hospital and NBSS records were analysed to identify patients treated with VAB and mammographic surveillance alone and to determine outcome over a follow-up period of 52−142 months (median 85).

Results

Ten per cent progressed directly to surgery (13/129). A total of 116 were followed mammographically after VAB with no surgical intervention (49 ADH, 2 ALH, 21 LCIS, 44 atypia (not otherwise specified)). Nine patients re-presented to the service with invasive carcinoma (six ipsilateral) and two with DCIS (both ipsilateral) between 12 and 80 months. The ipsilateral re-presentation rate was highest for ADH (5/49) and LCIS (2/21). In the absence of ADH or LCIS, the only ipsilateral representation was one low-grade DCIS, 62 months after VAB.

Conclusion

Re-presentation with ipsilateral carcinoma following VAB excision for ADH and LCIS is comparable to surgical excision for ADH and LCIS. National guidance is required.

Authors’ Affiliations

(1)
Castle Hill Hospital, Cottingham, UK
(2)
Hull and East Yorkshire Medical School, Hull, UK

Copyright

Advertisement